BioCryst Pharmaceuticals Inc. (BCRX) Rating Lowered to Sell at Zacks Investment Research
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
Several other research analysts have also commented on the stock. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. FBR & Co reiterated a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, July 6th. Piper Jaffray Cos. upgraded shares of BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $5.00 to $8.00 in a research note on Friday, August 12th. Jefferies Group lifted their price target on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the stock a “hold” rating in a research note on Friday, August 5th. Finally, JMP Securities cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $8.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 4.60 on Tuesday. The company’s 50 day moving average is $4.43 and its 200 day moving average is $3.53. BioCryst Pharmaceuticals has a 1-year low of $1.63 and a 1-year high of $11.74. The company’s market cap is $339.02 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.04. BioCryst Pharmaceuticals had a negative net margin of 285.24% and a negative return on equity of 187.98%. The business earned $4.80 million during the quarter, compared to analysts’ expectations of $3.92 million. During the same period last year, the business earned $0.06 earnings per share. The business’s revenue for the quarter was down 81.4% on a year-over-year basis. Equities research analysts forecast that BioCryst Pharmaceuticals will post ($1.03) EPS for the current year.
In other news, insider Thomas R. Staab II sold 5,864 shares of the company’s stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $5.18, for a total transaction of $30,375.52. Following the completion of the transaction, the insider now owns 128,745 shares of the company’s stock, valued at approximately $666,899.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Alane P. Barnes sold 8,357 shares of the company’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $4.27, for a total transaction of $35,684.39. Following the transaction, the vice president now directly owns 79,377 shares of the company’s stock, valued at approximately $338,939.79. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services Inc increased its position in BioCryst Pharmaceuticals by 15.7% in the second quarter. Commonwealth Equity Services Inc now owns 40,255 shares of the biotechnology company’s stock worth $114,000 after buying an additional 5,450 shares in the last quarter. HBK Investments L P increased its stake in BioCryst Pharmaceuticals by 152.7% in the first quarter. HBK Investments L P now owns 49,773 shares of the biotechnology company’s stock worth $141,000 after buying an additional 30,073 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $180,000. ProShare Advisors LLC increased its stake in BioCryst Pharmaceuticals by 1.4% in the second quarter. ProShare Advisors LLC now owns 63,843 shares of the biotechnology company’s stock worth $181,000 after buying an additional 876 shares during the period. Finally, Quantitative Systematic Strategies LLC acquired a new stake in BioCryst Pharmaceuticals during the second quarter worth about $186,000. 70.34% of the stock is owned by institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.